Amplification and mutation of the epidermal growth factor receptor (EGFR) represents crucial genetic signature in GSCs and mAbs directly targeting EGFR is used as a well-known therapeutic approach in glioma. The gene discussed is EGFR; the disease is central nervous system cancer.